Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Introduction to zonisamide.

Michel Baulac1

  • 1Department of Neurology, University of Paris 6, Bat. Paul Castaigne, Hopital de la Pitie-Salpetriere, 47 Bld de l'Hopital, 75013 Paris, France. michel.baulac@psl.ap-hop-paris.fr

Epilepsy Research
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force.

Epilepsia open·2021
Same author

FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force.

Epilepsy currents·2021
Same author

Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.

Epilepsy research·2021
Same author

Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.

Epilepsia·2020
Same author

Loss-of-Function Mutations in NR4A2 Cause Dopa-Responsive Dystonia Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2020
Same author

Conscious and unconscious expectancy effects: A behavioral, scalp and intracranial electroencephalography study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2019
Same journal

Comment on "Predictors of surgical outcome in frontal lobe epilepsy: Experience from a single-center cohort in Latin America".

Epilepsy research·2026
Same journal

Response to: "A critical appraisal of principal component analysis of antiseizure medication-induced hostility/aggression and factor analysis of levetiracetam".

Epilepsy research·2026
Same journal

Access to inpatient video-EEG monitoring for patients with frequent seizure-related emergency visits.

Epilepsy research·2026
Same journal

Effect of the ketogenic diet on absence seizures in rats with genetic absence epilepsy.

Epilepsy research·2026
Same journal

Diagnostic accuracy of artificial intelligence models for seizure outcome prediction after epilepsy surgery: A systematic review and meta-analysis.

Epilepsy research·2026
Same journal

Quality assessment of persian epilepsy mobile applications: A systematic review using uMARS and DISCERN.

Epilepsy research·2026
See all related articles

Zonisamide is a novel antiepileptic drug (AED) effective for partial seizures. It offers a favorable pharmacokinetic profile and a well-defined safety profile, making it a valuable addition to epilepsy treatment.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Zonisamide (Zonegran) is an antiepileptic drug (AED) with extensive clinical use in Japan and the United States.
  • It is approved in Europe for adjunctive therapy in adults with refractory partial seizures.

Purpose of the Study:

  • To define the pharmacologic and clinical profiles of zonisamide based on 14 years of accumulated clinical experience.
  • To highlight its unique mechanisms of action and therapeutic advantages in epilepsy management.

Main Methods:

  • Review of extensive clinical data and accumulated experience over a 14-year period.
  • Analysis of zonisamide's structural distinctiveness, mechanisms of action, pharmacokinetics, and drug interactions.

Main Results:

  • Zonisamide exhibits multiple complementary mechanisms of action, contributing to broad efficacy in epilepsy.

Related Experiment Videos

  • It allows once-daily dosing due to a long half-life (T1/2) and demonstrates linear pharmacokinetics.
  • Minimal drug interactions were observed; plasma levels of other AEDs and oral contraceptives remain unaffected.
  • Effective seizure control (up to 51% reduction) achieved at doses ≥300 mg/day, with established dosing schedules.
  • Adverse events are primarily central nervous system-related and manageable with appropriate patient care.

    • Conclusions:

    • Zonisamide possesses desirable characteristics for an AED, including a distinct mechanism, favorable pharmacokinetics, and a well-defined safety profile.
    • It represents a valuable therapeutic option for epilepsy treatment, particularly for refractory partial seizures.